Please assess the completion status of the following clinical trial:

Trial Title: Extended Dosing With Eltrombopag for Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Previous diagnosis of refractory severe aplastic anemia and following at least one treatment course of immunosuppression with a regimen containing antithymocyte globulin, alemtuzumab or cyclophosphamide.~* One or more of the following three clinically-significant cytopenias: platelet count less than or equal to 30,000/micro L or platelet-transfusion-dependence (requiring at least 4 platelet transfusions in the 8 weeks prior to study entry); neutrophil count less than 500/micro L; hemoglobin less than 9.0 g/dL or red cell transfusion-dependence (requiring at least 4 units of PRBCs in the eight weeks prior to study entry)~* Age greater than or equal to 2 years old~* Weight \> 12 kg~EXCLUSION CRITERIA:~* Infection not adequately responding to appropriate therapy~* Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry.~* Creatinine \> 2.5 mg/dL~* Direct Bilirubin \> 2.0 mg/dL~* SGOT or SGPT \>5 times the upper limit of normal~* Hypersensitivity to eltrombopag or its components\<TAB\>~* Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~* Unable to understand the investigational nature of the study or give informed consent~* Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 7-10 days is likely~* Treatment with ATG, cyclophophamide or alemtuzamab within 6 months of study entry.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Administration of eltrombopag at a dose of 150mg/day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).